Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2019

View Archived Issues

Clinical testing approved for the third-generation EGFR inhibitor XZP-5809

Gene minimizes mitotic chromosomal aberrations

FDA clears IND for phase I trial of BTX-A51 for AML and MDS

Results from a phase IIa study of reldesemtiv in patients with COPD

First-in-human results presented for adjuvant DC vaccine in patients with high-risk prostate cancer

Preliminary results of precision medicine-directed umbrella study of CCT301-38 and CCT301-59

First patient enrolled in phase III FALCON trial of bardoxolone for the treatment of AKPKD

Promising phase II efficacy data presented for NRX-101

CD206 plays a prognostic role in patients with DM/ILD

TP-0903 advances into phase Ib expansion stage in patients with advanced solid tumors

Inflazome patents new NLRP3 inflammasome inhibitors

Takeda identifies hSTING agonists

CSIR synthesizes new TLR9 antagonists

Shanghai ECUST Biomedicine patents tubulin polymerization inhibitors

Beijing Jialin Pharmaceutical discovers SMARCA2-targeting drugs for cancer

Patient recruitment ongoing in phase I study of BOS-475

Nonclinical toxicology studies support long-term administration of oral ibrexafungerp

First-in-human data for M-2000 in patients with early-stage breast cancer

Shionogi & Co. patents new antibacterial compounds

GT Biopharma provides clinical update for two phase I/II studies of GTB-1550

IVI and MCRI to coordinate global push to develop vaccine against Strep A

First study to test osilodrostat in children and adolescents with Cushing's disease

First patient dosed in phase I study of ALN-AGT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...